


Listing of Claims:

This listing of claims will replace all prior listings of claims in the application.

Claims 1-74 (cancelled)

Claim 75(new) 1. A compound of formula I,



wherein,

X is Cl, Br, F, CN or NO₂;

G is (a) C₁₋₇alkyl which partially unsaturated and is substituted by hydroxy, or


(b) C₁₋₄alkyl substituted by NR¹R² or 4-tetrahydropyran;

R¹ is C₂₋₇alkyl substituted by hydroxy, C₁₋₄alkoxy, aryl, or heteroaryl;


R² is hydrogen or C₁₋₇alkyl;

or R¹ and R² together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C₁₋₇alkyl;


W is a heterocycle of formula W1.1-1.19, W1.21-1.23, W3.1-3.3, W3.5-3.11 W3.13-3.14, or W4;




W1.1




W1.2




W1.3




W1.4




W1.5




W1.6




W1.7




W1.8




W1.9




W1.10




W1.11




W1.12




W1.13




W1.14



W1.15




W1.16



W1.17




W1.18




W1.19




W1.21




W1.22




W1.23




W3.1




W3.2




W3.3



W3.5




W3.6




W3.7




W3.8




W3.9




W3.10




W3.11



W3.13



W3.14



W4

wherein

R⁴ is H, halogen, or C₁₋₄alkyl optionally substituted by one to three halogens;

- R⁵ is
- (a) H,
 - (b) halo,
 - (c) OR¹²,
 - (d) SR¹²,
 - (e) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
 - (f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
 - (g) (C=O)R⁹,
 - (h) S(O)_mR⁹,
 - (i) (C=O)OR²,
 - (j) NHSO₂R⁹,
 - (k) nitro, or
 - (l) cyano;

- R⁶ is
- (a) H,
 - (b) halo,
 - (c) aryl,
 - (d) het,
 - (e) OR¹²,
 - (f) SR¹²,
 - (g) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, aryl, halo, C₃₋₈cycloalkyl optionally substituted by OR¹², or het attached through a carbon atom,
 - (h) NR¹⁰R¹¹,
 - (i) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
 - (j) (C=O)R⁹,
 - (k) S(O)_mR⁹,
 - (l) (C=O)OR²,
 - (m) NHSO₂R⁹,
 - (n) nitro, or

- (o) cyano;
- R⁷ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- (c) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR¹², SR¹², or NR¹⁰R¹¹,
- (d) aryl, or
- (e) het;
- R⁸ is (a) H,
- (b) C₁₋₇alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR¹², SR¹², NR¹⁰R¹¹, or halo,
- (c) OR¹², or
- (d) SR¹²;
- R⁹ is (a) C₁₋₇alkyl,
- (b) NR¹⁰R¹¹,
- (c) aryl, or
- (d) het, wherein said het is bound through a carbon atom;
- R¹⁰ and R¹¹ are independently
- (a) H,
- (b) aryl,
- (c) C₁₋₇alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from CONR²R², CO₂R², het, aryl, cyano, or halo,
- (d) C₂₋₇alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR²R², OR², or SR²,
- (e) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R², or
- (f) R¹⁰ and R¹¹ together with the nitrogen to which they are attached form a het;
- R¹² is (a) H,
- (b) aryl,
- (c) het
- (d) C₁₋₇alkyl optionally substituted by aryl, het, or halogen,
- (e) C₂₋₇alkyl substituted by OR², SR², or NR²R², or

- (f) C₃₋₈cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR², SR², or NR²R²;

each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR²R², CO₂R², CF₃, C₁₋₆alkoxy, and C₁₋₆ alkyl which maybe further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO₂R², CF₃, C₁₋₆alkoxy, oxo, oxime, and C₁₋₆ alkyl which may be further substituted by one to three SR², NR²R², OR², or CO₂R² groups;

halo or halogen is F, Cl, Br, I;

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);
and a pharmaceutically acceptable salt thereof.

76(new) The compound according to claim 75, wherein X is Cl.

77(new) The compound according to claim 75 wherein G is 4-morpholinylmethyl.

78(new) The compound according to claim 75 wherein G is 3-hydroxy-1-propynyl.

79(new) The compound according to claim 75 wherein G is tetrahydro-2H-pyran-4-ylmethyl.

80(new) The compound according to claim 75 which is
N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-2-oxo-2H-pyrano[2,3-*c*]pyridine-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1H-isochromene-3-carboxamide;
N-(4-chlorobenzyl)-4-hydroxy-1-oxo-6-(tetrahydro-2H-pyran-4-ylmethyl)-1H-isochromene-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1*H*-isochromene-3-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)-8-oxo-7,8-dihydro[1,7]naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,5]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,5]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)[1,7]naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)[1,7]naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,7]naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)-3-isoquinolinecarboxamide; or a pharmaceutically acceptable salt thereof.

81(new) A pharmaceutical composition comprising a compound of claim 75 and a pharmaceutically acceptable carrier.

82(new) A method of treating or preventing a viral infection comprising administering to a mammal in need of such treatment a compound of claim 75.

83(new) The method according to claim 82 wherein said viral infection is a herpes virus infection.

84(new) The method according to claim 82 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type 6, 7, or 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

85(new) The method according to claim 82 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

86(new) The method according to claim 82 wherein the amount administered is from about 0.1 to about 300 mg/kg of body weight.


87(new) The method according to claim 48 wherein the amount administered is from about 1 to about 30 mg/kg of body weight.

88(new) The method according to claim 48 wherein the compound is administered parenterally, topically, intravaginally, orally, or rectally.

REMARKS

Applicants believe that the Preliminary Amendments introduce no new matter.

Respectfully submitted,



Lucy X. Yang, Attorney
Registration No. 40,259

Date: 3-29-2004

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-9536 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316